UK Regulators Probe Private Clinics Over Unsubstantiated Peptide Therapy Claims
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a formal investigation into private clinics that are offering unregulated peptide therapies, accompanied by unverified health claims. This investigation was sparked by revelations that several clinics are making potentially illegal claims about experimental peptide treatments for anti-aging, injury recovery, and cognitive enhancement.
Despite the growing interest in peptide therapies, promoted by influencers and some medical professionals, the scientific evidence supporting many of these health claims is limited. The majority of existing studies have been conducted on animal models, with large-scale human clinical trials being notably absent.
As reported by The Guardian, several UK clinics have been found advertising peptides such as BPC-157 for tissue repair, Cortexin for cognitive enhancement, and Thymosin Alpha for immune function. The MHRA has clarified that if clinics make medicinal claims for peptide treatments, these products are then classified as medicines. As such, they are subject to strict regulation under the Human Medicines Regulations 2012.
“We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations,” stated Lynda Scammell, head of borderline products at the MHRA.
The agency has confirmed that it will take appropriate regulatory action against any clinics identified as breaching legal requirements. This marks a significant crackdown on the rapidly expanding gray-market peptide industry.
Source: Global Cosmetics News